Kura Oncology Inc
Veridion Score
Composite trend over time
Why is KURA moving today?
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for KURA.
KURA insider activity
Kura Oncology Inc
No multi-insider buying cluster in the last 90 days
Net selling: -$1.9M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-22 | 2026-06-18 | Leoni Mollie | Insider | sell | $9.82 | 84,929 | 182,345 | $834K | SEC Form 4 |
| 2026-05-22 | 2026-05-21 | Powl Brian T. | Insider | sell | $11.00 | 10,000 | 173,614 | $110K | SEC Form 4 |
| 2026-05-20 | 2026-05-19 | FORD KATHLEEN | Insider | sell | $9.08 | 2,257 | 153,560 | $20K | SEC Form 4 |
| 2026-05-20 | 2026-05-19 | Powl Brian T. | Insider | sell | $9.21 | 339 | 183,614 | $3K | SEC Form 4 |
| 2026-05-20 | 2026-05-18 | Bair Teresa Brophy | Insider | sell | $9.38 | 2,256 | 226,931 | $21K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 36 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moKURA contract awards, year to date.
Public federal awards linked to this ticker.
KURA lobbying filings, year to date.
Registered lobbying filings matched to Kura Oncology Inc.